DURECT Corp (NASDAQ: DRRX) announced that, based on feedback from the FDA, it plans to conduct a new POSIDUR (SABER-Bupivacaine) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE